Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer-Reference-Cited by-同舟云学术

Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer

Published:2023-10-02 Issue:6 Volume:30 Page:1085-1093
ISSN:1340-6868
Container-title:Breast Cancer
language:en
Short-container-title:Breast Cancer

Author:

Kusama Hiroki^ORCID,Kittaka Nobuyoshi^ORCID,Soma Ai,Taniguchi Azusa,Kanaoka Haruka,Nakajima Satomi,Oyama Yuri,Seto Yukiko,Okuno Jun,Watanabe Noriyuki,Matsui Saki,Nishio Minako^ORCID,Fujisawa Fumie^ORCID,Honma Keiichiro^ORCID,Tamaki Yasuhiro^ORCID,Nakayama Takahiro^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12282-023-01504-y.pdf

Reference34 articles.

1. den Brok WD, Speers CH, Gondara L, Baxter E, Tyldesley SK, Lohrisch CA. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res Treat. 2017;161(3):549–56. https://doi.org/10.1007/s10549-016-4080-9.

2. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72. https://doi.org/10.1016/S0140-6736(13)62422-8.

3. Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al. KEYNOTE-522 Investigators. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556–67. https://doi.org/10.1056/NEJMoa2112651.

4. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21. https://doi.org/10.1038/nature12477.

5. Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50. https://doi.org/10.1016/S1470-2045(17)30904-X.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer—A Systematic Review and Meta-Analysis;Current Oncology;2024-08-03

2. Neoadjuvant radiotherapy in ER+, HER2+, and triple-negative -specific breast cancer based humanized tumor mice enhances anti-PD-L1 treatment efficacy;Frontiers in Immunology;2024-04-29

3. Diagnostic and prognostic performance of the neutrophil-to-lymphocyte ratio in acute coronary syndromes: A meta-analysis of 90 studies including 45 990 patients;Polish Heart Journal;2024-03-28

4. Comparison of the effectiveness of neoadjuvant chemotherapy and adjuvant chemotherapy for improving prognosis in triple-negative breast cancer patients;American Journal of Translational Research;2024

5. Peripheral blood inflammatory indexes in breast cancer: A review;Medicine;2023-12-01